33.16

0.58% 0.2011

Capricor Therapeutics Inc (CAPR)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt CAPR? Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$32.96

Offen:

$33.14

24-Stunden-Volumen:

46,066

Relative Volume:

0.04

Marktkapitalisierung:

$1.92B

Einnahmen:

$11.13M

Nettoeinkommen (Verlust:

$-105.04M

KGV:

-14.70

EPS:

-2.2565

Netto-Cashflow:

$-81.54M

1W Leistung:

+2.13%

1M Leistung:

+4.64%

6M Leistung:

+427.87%

1J Leistung:

+354.11%

1-Tages-Spanne:

$32.88

$33.33

1-Wochen-Bereich:

$30.82

$34.64

52-Wochen-Spanne:

$4.30

$40.37

Capricor Therapeutics Inc Stock (CAPR) Company Profile

Firmenname

Capricor Therapeutics Inc

Sektor

Healthcare (1107)

Branche

Biotechnology (615)

Telefon

(310) 358-3200

Adresse

10865 ROAD TO THE CURE, SAN DIEGO, CA

Mitarbeiter

231

Twitter

@Capricor

Nächster Verdiensttermin

2026-05-12

Neueste SEC-Einreichungen

CAPR's Discussions on Twitter

Compare CAPR vs VRTX, REGN, ARGX, ALNY, ONC

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
CAPR Capricor Therapeutics Inc	33.12	1.91B	11.13M	-105.04M	-81.54M	-2.2565
VRTX Vertex Pharmaceuticals Inc	426.24	107.87B	12.32B	4.34B	3.19B	16.86
REGN Regeneron Pharmaceuticals Inc	705.05	73.63B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	804.29	49.42B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	299.67	40.20B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	302.60	33.06B	5.36B	287.73M	924.18M	2.5229

Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-06-30	Eingeleitet	Alliance Global Partners	Buy
2025-06-26	Eingeleitet	B. Riley Securities	Buy
2025-05-20	Eingeleitet	Roth Capital	Buy
2024-10-21	Eingeleitet	Piper Sandler	Overweight
2024-05-17	Eingeleitet	Oppenheimer	Outperform
2024-01-05	Eingeleitet	Cantor Fitzgerald	Overweight
2022-10-26	Eingeleitet	Ladenburg Thalmann	Buy
2018-12-26	Herabstufung	Maxim Group	Buy → Hold
2018-01-26	Bestätigt	H.C. Wainwright	Buy
2017-09-15	Bestätigt	H.C. Wainwright	Buy
2017-02-13	Fortgesetzt	Rodman & Renshaw	Buy
2016-07-06	Fortgesetzt	H.C. Wainwright	Buy
2016-06-15	Eingeleitet	ROTH Capital	Buy

Alle ansehen

Capricor Therapeutics Inc Aktie (CAPR) Neueste Nachrichten

May 04, 2026

CAPR stock in focus: Ex-exec eyed for FDA role says drug approvals are not 'best-in-class' signals - MSN

May 04, 2026

Biotech Capricor pairs Q1 results with a corporate update May 12 - Stock Titan

May 04, 2026

Capricor (NASDAQ: CAPR) EVP sells 25K shares under 10b5-1 plan - Stock Titan

May 04, 2026

Capricor (NASDAQ: CAPR) CFO exercises options, sells 25,000 shares under 10b5-1 plan - Stock Titan

May 04, 2026

Capricor Therapeutics to Report First Quarter 2026 Financial Results and Provide Recent Corporate Update on May 12 - marketscreener.com

May 04, 2026

Capricor Therapeutics (CAPR) Is Down 12.4% After New HOPE-3 Deramiocel Phase 3 Data ReleaseWhat's Changed - Sahm

May 04, 2026

CAPR Stock In Focus: Ex-Exec Eyed For FDA Role Says Drug Approvals Are Not ‘Best-In-Class’ Signals - Stocktwits

May 04, 2026

May 01, 2026

Capricor Therapeutics (NASDAQ:CAPR) Stock Price Down 6.5%What's Next? - MarketBeat

May 01, 2026

Apr 29, 2026

Moody Aldrich Partners LLC Takes Position in Capricor Therapeutics, Inc. $CAPR - MarketBeat

Apr 29, 2026

CAPR Forecast, Price Target & Analyst Ratings | CAPRICOR THERAPEUTICS INC (NASDAQ:CAPR) - ChartMill

Apr 29, 2026

Apr 27, 2026

Top 10 healthcare stocks by forward P/E: From Capricor's 418x to Alignment Healthcare's 48x - MSN

Apr 27, 2026

Apr 26, 2026

Understanding the Setup: (CAPR) and Scalable Risk - Stock Traders Daily

Apr 26, 2026

CAPR stock draws investor attention after AAN presentation for DMD therapy - MSN

Apr 26, 2026

Assessing Capricor Therapeutics (CAPR) Valuation After HOPE-3 Phase 3 Data And BLA Review Progress - Sahm

Apr 26, 2026

Apr 24, 2026

How Phase 3 HOPE-3 DMD Data And BLA Review At Capricor Therapeutics (CAPR) Has Changed Its Investment Story - Yahoo Finance

Apr 24, 2026

We're Not Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn - Yahoo Finance

Apr 24, 2026

Roth Capital Maintains Capricor Therapeutics (CAPR) Buy Recommendation - MSN

Apr 24, 2026

Apr 23, 2026

Capricor Therapeutics Announces Late-Breaking Presentation of HOPE-3 Phase 3 Results at the American Academy of Neurology 2026 Annual Meeting - Sahm

Apr 23, 2026

CAPR (Capricor Therapeutics Inc.) reports wider than expected Q4 2025 loss, stock notches small gain in daily trading. - Xã Thanh Hà

Apr 23, 2026

Apr 22, 2026

CAPR (Capricor Therapeutics Inc.) reports wider Q4 2025 loss than estimates, shares dip 1.28% in today's trading.Expert Stock Picks - Cổng thông tin điện tử tỉnh Tây Ninh

Apr 22, 2026

CAPR (Capricor Therapeutics) EV-to-OCF : -24.77 (As of Apr. 28, 2026) - GuruFocus

Apr 22, 2026

Capricor Therapeutics Announces Late-Breaking Presentation - GlobeNewswire

Apr 22, 2026

How Investors May Respond To Capricor Therapeutics (CAPR) HOPE-3 Data and Pending FDA Decision - Sahm

Apr 22, 2026

Apr 20, 2026

Capricor (CAPR) Stock: Why Margin Expansion (Extends Gains) 2026-04-20Expert Breakout Alerts - UBND thành phố Hải Phòng

Apr 20, 2026

Apr 17, 2026

CAPR Stock Gains Steam: Former Capricor Exec Could Become FDA’s Top Gene Therapy Regulator Ahead Of High-Stakes DMD Decision - Stocktwits

Apr 17, 2026